Clinical Trials of Immunomodulatory Therapies in Severe Sepsis and Septic Shock
Open Access
- 15 April 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 34 (8) , 1084-1093
- https://doi.org/10.1086/339549
Abstract
Sepsis remains one of the leading causes of mortality in critically ill patients. Increased insight into the complexities of this disease process hasKeywords
This publication has 135 references indexed in Scilit:
- Nitric oxide (NO) production correlates with renal insufficiency and multiple organ dysfunction syndrome in severe sepsisIntensive Care Medicine, 1996
- Monocyte deactivation-rationale for a new therapeutic strategy in sepsisIntensive Care Medicine, 1996
- Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shockCritical Care Medicine, 1996
- Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shockIntensive Care Medicine, 1995
- Treatment of purpura fulminans in meningococcemia with protein C concentrateThe Journal of Pediatrics, 1995
- Effect of ibuprofen in patients with severe sepsisCritical Care Medicine, 1991
- Effect of High-Dose Glucocorticoid Therapy on Mortality in Patients with Clinical Signs of Systemic SepsisNew England Journal of Medicine, 1987
- A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 1987
- Reduction of Mortality in Chloramphenicol-Treated Severe Typhoid Fever by High-Dose DexamethasoneNew England Journal of Medicine, 1984
- Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a MutantEscherichia coliNew England Journal of Medicine, 1982